Terms: = Lymphoma AND ERCC2, TTD, 2068, ENSG00000104884, COFS2, P18074, MGC102762, XPD, MGC126219, MGC126218, EM9
59 results:
1. Disparities in Time to Diagnosis Among Patients With Multiple Myeloma.
Lin OM; Paine D; Gramling E; Menon M
Clin Lymphoma Myeloma Leuk; 2023 Nov; 23(11):e379-e385. PubMed ID: 37612207
[TBL] [Abstract] [Full Text] [Related]
2. Real-world time to discontinuation of first-line venetoclax + obinutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma.
Lu X; Emond B; Qureshi ZP; Wu LH; Forbes SP; Hilts A; Liu S; Lafeuille MH; Lefebvre P; Huang Q; Rogers KA
Curr Med Res Opin; 2023 Sep; 39(9):1227-1235. PubMed ID: 37530387
[TBL] [Abstract] [Full Text] [Related]
3. [Blaps rynchopetera affects proliferation, migration, and invasion of non-small cell lung cancer: a study based on network pharmacology and in vivo and in vitro experiments].
Li XY; Ma K; Yan JN; You FC; Ma L
Zhongguo Zhong Yao Za Zhi; 2023 Jul; 48(13):3576-3588. PubMed ID: 37474991
[TBL] [Abstract] [Full Text] [Related]
4. Real-World Persistence and Time to Next Treatment With Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke.
Narezkina A; Akhter N; Lu X; Emond B; Panjabi S; Forbes SP; Hilts A; Liu S; Lafeuille MH; Lefebvre P; Huang Q; Choi M
Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):e959-e971. PubMed ID: 35973891
[TBL] [Abstract] [Full Text] [Related]
5. Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States.
Jahanzeb M; Lin HM; Wu Y; Zhang P; Gorritz M; McGuiness CB; Huang WT; Sun K; Chen CC; Camidge DR
Oncologist; 2022 Sep; 27(9):790-798. PubMed ID: 35781589
[TBL] [Abstract] [Full Text] [Related]
6. Life-threatening infections during treatment for acute lymphoblastic leukemia on the Malaysia-Singapore 2003 and 2010 clinical trials: A risk prediction model.
Oh BLZ; Fan L; Lee SHR; Foo KM; Chiew KH; Seeto ZZL; Chen ZW; Neoh CCC; Liew GSM; Eng JJ; Lam JCM; Quah TC; Tan AM; Chan YH; Yeoh AEJ
Asia Pac J Clin Oncol; 2022 Oct; 18(5):e456-e468. PubMed ID: 35134276
[TBL] [Abstract] [Full Text] [Related]
7. Deviation from delivery of radiation therapy to childhood cancer patients: A retrospective audit.
Agrawal R; Goel V; Anand A; Arora RS
Pediatr Blood Cancer; 2022 Feb; 69(2):e29462. PubMed ID: 34842336
[TBL] [Abstract] [Full Text] [Related]
8. Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma.
Zinzani PL; Ramchandren R; Santoro A; Paszkiewicz-Kozik E; Gasiorowski R; Johnson NA; de Oliveira JSR; Buccheri V; Perini GF; Dickinson M; McDonald A; Özcan M; Sekiguchi N; Zhu Y; Raut M; Saretsky TL; Nahar A; Kuruvilla J
Blood Adv; 2022 Jan; 6(2):590-599. PubMed ID: 34644372
[TBL] [Abstract] [Full Text] [Related]
9. Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data.
Dudnik E; Moskovitz M; Rottenberg Y; Lobachov A; Mandelboim R; Shochat T; Urban D; Wollner M; Nechushtan H; Rotem O; Zer A; Daher S; Bar J;
Oncoimmunology; 2021 Jan; 10(1):1865653. PubMed ID: 33552685
[TBL] [Abstract] [Full Text] [Related]
10. Interdisciplinary approach to multiple myeloma - time to diagnosis and warning signs.
Herget GW; Kälberer F; Ihorst G; Graziani G; Klein L; Rassner M; Gehler C; Jung J; Schmal H; Wäsch R; Engelhardt M
Leuk Lymphoma; 2021 Apr; 62(4):891-898. PubMed ID: 33225781
[TBL] [Abstract] [Full Text] [Related]
11. Brigatinib in
Heredia D; Barrón F; Cardona AF; Campos S; Rodriguez-Cid J; Martinez-Barrera L; Alatorre J; Salinas MÁ; Lara-Mejia L; Flores-Estrada D; Arrieta O
Future Oncol; 2021 Jan; 17(2):169-181. PubMed ID: 32986959
[No Abstract] [Full Text] [Related]
12. Predicting Mortality after Autologous Transplant: Development of a Novel Risk Score.
Berro M; Chhabra S; Piñana JL; Arbelbide J; Rivas MM; Basquiera AL; Vitriu A; Requejo A; Milovic V; Yantorno S; Bentolila G; Garcia JJ; Castro M; Palmer S; Saslavsky M; Duarte P; Cerutti A; Jarchum G; Tisi Baña M; Thapa B; Solano C; Sureda A; Rovira M; Shaw BE; Kusminsky G;
Biol Blood Marrow Transplant; 2020 Oct; 26(10):1828-1832. PubMed ID: 32640312
[TBL] [Abstract] [Full Text] [Related]
13. Real-world treatment duration in ALK-positive non-small-cell lung cancer patients receiving brigatinib through the early access program.
Lin HM; Pan X; Hou P; Allen S; Baumann P; Hochmair MJ
Future Oncol; 2020 May; 16(15):1031-1041. PubMed ID: 32338548
[No Abstract] [Full Text] [Related]
14. Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer.
Pérol M; Pavlakis N; Levchenko E; Platania M; Oliveira J; Novello S; Chiari R; Moran T; Mitry E; Nüesch E; Liu T; Balas B; Konopa K; Peters S
Lung Cancer; 2019 Dec; 138():79-87. PubMed ID: 31654838
[TBL] [Abstract] [Full Text] [Related]
15. Achieving a timely diagnosis for teenagers and young adults with cancer: the ACE "too young to get cancer?" study.
Dommett RM; Pring H; Cargill J; Beynon P; Cameron A; Cox R; Nechowska A; Wint A; Stevens MCG
BMC Cancer; 2019 Jun; 19(1):616. PubMed ID: 31234813
[TBL] [Abstract] [Full Text] [Related]
16. Genetic Polymorphisms in Inflammatory and Other Regulators in Gastric Cancer: Risks and Clinical Consequences.
Rudnicka K; Backert S; Chmiela M
Curr Top Microbiol Immunol; 2019; 421():53-76. PubMed ID: 31123885
[TBL] [Abstract] [Full Text] [Related]
17. Allogeneic Stem Cell Transplantation in Patients With FLT3-ITD Mutated AML: Transplantation in CR1 Is the Decisive Factor for Good Outcome.
Jindra P; Raida L; Karas M; Szotkowski T; Lysák D; Hrabětová M; Jungová A; Steinerová K; Faber E; Papajík T
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):462-469. PubMed ID: 31109905
[TBL] [Abstract] [Full Text] [Related]
18. An Age Stratified Analysis of the Access to Care Continuum Across Three Tumor Groups: Are There Delays for AYA?
Pettit T; Sue L; Waugh V; Ballantine K; Gardner K; Bremer L; Pemberton L; Allison L; Adams S; Chou E; Spearing R
J Adolesc Young Adult Oncol; 2019 Aug; 8(4):402-409. PubMed ID: 30912693
[No Abstract] [Full Text] [Related]
19. Association of ercc2 Gene Polymorphisms with Susceptibility to Diffuse Large B-Cell lymphoma.
Tong Y; Xiang Y; Li B; Bao S; Zhou Y; Yuan W; Ling Y; Hao D; Zhu H; Sun Z
Med Sci Monit; 2018 Oct; 24():7015-7022. PubMed ID: 30279407
[TBL] [Abstract] [Full Text] [Related]
20. Health-related quality of life in adults with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab.
Topp MS; Zimmerman Z; Cannell P; Dombret H; Maertens J; Stein A; Franklin J; Tran Q; Cong Z; Schuh AC
Blood; 2018 Jun; 131(26):2906-2914. PubMed ID: 29739753
[TBL] [Abstract] [Full Text] [Related]
[Next]
